GlassScriptPhysician profile
Joan M Tobar
NPI 1366057671
$2,167.00
in general payments reported to CMS, 2019-2025
25 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $412 · 2023: $451 · 2024: $395 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376 · Education: $18.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.54 |
| Education | $18.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $338.07 | 2021-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $237.14 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $161.64 | 2021-2022 | |
| Medtronic, INC. | $147.87 | 2025 | Symplicity G3 |
| Amgen INC. | $137.81 | 2021-2024 | Tavneos |
| Novartis Pharmaceuticals Corporation | $133.81 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $127.58 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $117.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $93.99 | 2022-2024 | Farxiga, Lokelma |
| Genzyme Corporation | $75.04 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $73.18 | 2021-2023 | Velphoro, Korsuva |
| Novo Nordisk INC | $73.10 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $70.96 | 2021-2024 | Injectafer |
| Mallinckrodt Hospital Products INC. | $60.87 | 2021-2023 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $44.60 | 2021-2023 | Veltassa, Korsuva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $41.18 | 2024 | Onpattro, Oxlumo |
| Ani Pharmaceuticals, INC. | $40.55 | 2024-2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $37.95 | 2025 | |
| Opko Pharmaceuticals, LLC | $34.53 | 2022-2024 | Rayaldee |
| Xeris Pharmaceuticals, INC. | $25.24 | 2025 | Keveyis |
| Chiesi USA, INC. | $21.98 | 2024 | Elfabrio |
| Apellis Pharmaceuticals, INC. | $21.04 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.22 | 2024 | Jardiance |
| Cormedix INC. | $18.99 | 2024 | Defencath |
| Travere Therapeutics, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Tobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.